XML 43 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2021
Income Taxes  
Schedule of Gross Deferred Tax Asset and Related Valuation Allowance

    

2021

    

2020

 

Deferred income tax assets:

Net operating loss carryforward

$

79,788,146

$

63,830,866

Capitalized start-up costs

 

920,516

 

1,114,309

Patent amortization

 

73,480

 

88,949

Research and orphan drug credits

 

47,976,370

 

42,008,797

Stock-based compensation

 

7,102,947

 

6,778,569

Operating lease liabilities

528,340

775,598

Accrued bonus

592,260

919,410

Other

209,580

283,751

Gross deferred income tax assets

 

137,191,639

 

115,800,249

Valuation allowance

 

(136,613,829)

 

(115,016,323)

Net deferred income tax assets

 

577,810

 

783,926

Deferred income tax liabilities:

Operating lease right-of-use assets

 

(433,727)

 

(639,843)

Property and equipment

 

(144,083)

 

(144,083)

Gross deferred income tax liabilities

 

(577,810)

 

(783,926)

Net deferred income tax asset/(liability)

$

$

Schedule of Reconciliations Between Statutory Federal Income Tax Rate and Effective Income Tax Rate of Income Tax Expense

    

2021

    

2020

    

2019

 

U.S. Federal statutory tax rate

 

21.0

%  

21.0

%  

21.0

%

State taxes

 

5.9

 

5.7

 

5.7

Research credit

 

0.9

 

0.7

 

0.8

Orphan drug credit

 

6.6

 

9.8

 

8.8

Other

(0.3)

0.4

(0.1)

Change in valuation allowance

 

(34.1)

 

(37.6)

 

(36.2)

Provision for income taxes

 

%

%

%